Physician profile
Steven Rosenfeld
NPI 1376643965
$3,660.40
in general payments reported to CMS, 2019-2025
24 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $236 · 2021: $329 · 2022: $730 · 2023: $351 · 2024: $1,495 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125 · Travel and Lodging: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.78 |
| Travel and Lodging | $867.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,555.70 | 2019-2024 | Clareon |
| Rxsight INC | $406.79 | 2021-2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $245.35 | 2019-2022 | |
| Abbvie INC. | $221.75 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Allergan, INC. | $184.30 | 2021-2022 | |
| Ocular Therapeutix, INC. | $163.61 | 2021-2023 | Dextenza |
| Dompe US, INC. | $128.78 | 2020-2024 | Oxervate |
| Glaukos Corporation | $117.45 | 2022 | |
| Sun Pharmaceutical Industries INC. | $107.88 | 2019 | |
| Tearlab Corp | $104.69 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.45 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $44.38 | 2024-2025 | Xdemvy |
| Amgen INC. | $44.06 | 2025 | Tepezza |
| Astellas Pharma US INC | $33.60 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $31.96 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $23.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.45 | 2020 | |
| Omeros Corporation | $19.88 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $17.77 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.03 | 2020 | |
| Horizon Therapeutics Plc | $16.02 | 2020 | |
| Bausch & Lomb Americas INC. | $14.64 | 2024 | Xiidra, Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rosenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.